Metastatic carcinoid and islet cell tumours of the pancreas: A phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin

Ph. Rougier, J. Oliveira, M. Ducreux, C. Theodore, J. Kac, J.P. Droz
{"title":"Metastatic carcinoid and islet cell tumours of the pancreas: A phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin","authors":"Ph. Rougier,&nbsp;J. Oliveira,&nbsp;M. Ducreux,&nbsp;C. Theodore,&nbsp;J. Kac,&nbsp;J.P. Droz","doi":"10.1016/0277-5379(91)90014-5","DOIUrl":null,"url":null,"abstract":"<div><p>A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m<sup>2</sup> per day (5-FU) for 3 days, 50 mg/m<sup>2</sup> doxorubicin on day 2, and 90 mg/m<sup>2</sup> cisplatin on day 2, repeated every 4 weeks. 24 patients, 20 non-pretreated and 4 pretreated, were included. For non-pretreated patients we observed 1 complete response and 2 partial responses. The response rate was 15% (95% confidence interval 0–31%). No response was observed in the pretreated patients. The toxicity was mainly digestive and haematological with 7 patients experiencing vomiting grade 3 and 3 patients with leucopenia grade 3. We conclude that the FAP protocol is of poor efficiency in endocrine tumours.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90014-5","citationCount":"48","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0277537991900145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 48

Abstract

A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m2 per day (5-FU) for 3 days, 50 mg/m2 doxorubicin on day 2, and 90 mg/m2 cisplatin on day 2, repeated every 4 weeks. 24 patients, 20 non-pretreated and 4 pretreated, were included. For non-pretreated patients we observed 1 complete response and 2 partial responses. The response rate was 15% (95% confidence interval 0–31%). No response was observed in the pretreated patients. The toxicity was mainly digestive and haematological with 7 patients experiencing vomiting grade 3 and 3 patients with leucopenia grade 3. We conclude that the FAP protocol is of poor efficiency in endocrine tumours.

胰腺转移性类癌和胰岛细胞肿瘤:5-氟尿嘧啶、阿霉素和顺铂联合化疗疗效的II期试验
一项针对类癌和胰岛细胞胰腺肿瘤的二期化疗试验采用FAP方案:5-氟尿嘧啶400mg /m2 /天(5-FU),连续3天,阿霉素50mg /m2第2天,顺铂90mg /m2第2天,每4周重复一次。纳入24例患者,其中20例未经预处理,4例经预处理。对于未接受治疗的患者,我们观察到1例完全缓解和2例部分缓解。应答率为15%(95%置信区间0-31%)。在预先治疗的患者中未观察到任何反应。毒性主要表现在消化和血液学方面,7例出现呕吐3级,3例出现白细胞减少3级。我们认为FAP治疗内分泌肿瘤的效果较差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信